The Global Health Body Sounds Alert Over Acute Shortage of Obesity Injections

Less than one in 10 individuals eligible to benefit from obesity jabs such as Wegovy can access them, caution the World Health Organization as it publishes its inaugural guidance on the drugs.

With in excess of 1,000,000,000 individuals worldwide now obese, it is urging increased and just access to GLP-1 medication.

According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.

"The latest guidance recognises that obesity is a long-term condition that can be treated with comprehensive and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and supply-chain constraints are significant hurdles to widespread availability to the injections that can assist patients in reducing considerable body mass, explains the body.

Skinny Jab Shortage

Despite the present best projected scenario, the supply of GLP-1 therapies could only cover around 100 million people – fewer than 10% of eligible patients, according to the health organization.

The recommendation calls on nations and manufacturers to widen access, by measures like voluntary licensing.

A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026.

How Weight-Loss Injections Function

The injections imitate a body's own hormone to slow digestion, reduce hunger and enhance the sense of being full so people consume fewer calories.

Individuals typically begin shedding pounds after several weeks of beginning the weekly injections.

Studies suggests patients may regain a significant portion within a year of halting the treatment, as their typical appetite come back.

To be above a healthy weight increases your likelihood for experiencing diseases, such as type 2 diabetes, heart disease, stroke, and specific malignancies.

Excess weight affects people in countries worldwide and was associated with millions of deaths worldwide in 2024, as per the health agency.